Dyadic International Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dyadic International, Inc. (DYAI) on November 9, 2021. The filing discloses the appointment of a new senior executive officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
Effective November 9, 2021, the Company appointed Joseph Hazelton as Chief Business Officer. Mr. Hazelton joins from Charleston Laboratories, Inc., bringing over 20 years of pharmaceutical industry experience.
Guidance, Outlook, and Compensation Details
The filing details the employment agreement entered into on November 1, 2021, with the following key terms:
- Base Salary: $240,000 annually.
- Cash Bonus: Eligible for an annual cash bonus up to 30% of base salary, determined 50% by results of operations and 50% by individual/corporate goals.
- Stock Options:
- Initial grant of 75,000 shares at the closing market price on November 9, 2021.
- Vesting Condition: The initial option vests upon the Company receiving cash from approved defined transactions initiated by Mr. Hazelton or a license agreement generating a cumulative $10 million in non-refundable cash within three years of the grant date.
- Eligibility for an additional 12,500 shares for the 2021 calendar year.
- Termination Benefits: If terminated without cause or for good reason, Mr. Hazelton is entitled to three months of base salary and benefits (if terminated on or before Nov 9, 2022) or six months (if terminated after that date), plus a potential prorated bonus at the Compensation Committee's discretion.
Investor Verification Checklist
- Verify the vesting conditions for the 75,000-share stock option grant, specifically the $10 million cash generation requirement.
- Review the full text of the Employment Agreement (Exhibit 10.1) for additional restrictive covenants or clauses not summarized in the 8-K.
- Confirm the Company's current cash position to assess the feasibility of the $10 million vesting milestone within the three-year window.
- Monitor future filings for the issuance of the 12,500-share annual award mentioned for 2021.